Arrowhead Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Arrowhead Pharmaceuticals
ARWR Stock  USD 69.33  0.21  0.30%   
Arrowhead Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Arrowhead Pharmaceuticals' valuation are provided below:
Gross Profit
829.4 M
Profit Margin
(0)
Market Capitalization
9.7 B
Enterprise Value Revenue
11.0006
Revenue
829.4 M
There are over one hundred nineteen available fundamental signals for Arrowhead Pharmaceuticals, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to validate Arrowhead Pharmaceuticals' prevailing fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. As of 01/31/2026, Market Cap is likely to grow to about 3.3 B. Also, Enterprise Value is likely to grow to about 3.3 B

Arrowhead Pharmaceuticals Total Revenue

1 Billion

Check Arrowhead Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arrowhead Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 22.5 M, Interest Expense of 97.6 M or Selling General Administrative of 106 M, as well as many indicators such as Price To Sales Ratio of 4.76, Dividend Yield of 0.0 or PTB Ratio of 9.35. Arrowhead financial statements analysis is a perfect complement when working with Arrowhead Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Arrowhead Stock
Check out the analysis of Arrowhead Pharmaceuticals Correlation against competitors.
To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.

Arrowhead Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.8 B1.7 B574.3 M
Slightly volatile
Short and Long Term Debt Total885.9 M843.7 M227.2 M
Slightly volatile
Other Current Liabilities154.7 M147.3 M43.5 M
Slightly volatile
Total Current Liabilities236.1 M224.8 M81.7 M
Slightly volatile
Property Plant And Equipment Net514.9 M490.4 M150.9 M
Slightly volatile
Accounts Payable21.3 M20.3 M9.6 M
Slightly volatile
Cash273.6 M260.5 M118.2 M
Slightly volatile
Non Current Assets Total603.5 M574.8 M208.7 M
Slightly volatile
Non Currrent Assets Other1.7 M1.6 M751.2 K
Slightly volatile
Cash And Short Term Investments1.1 B1.1 B353 M
Slightly volatile
Common Stock Total Equity239.1 K227.7 K169.6 K
Slightly volatile
Common Stock Shares Outstanding161.5 M153.8 M84.8 M
Slightly volatile
Liabilities And Stockholders Equity1.8 B1.7 B574.3 M
Slightly volatile
Other Current Assets29.5 M28.1 M10.8 M
Slightly volatile
Other Stockholder Equity2.5 B2.4 B986.4 M
Slightly volatile
Total Liabilities1.1 B1.1 B322.5 M
Slightly volatile
Property Plant And Equipment Gross611.7 M582.6 M170.5 M
Slightly volatile
Total Current Assets1.1 B1.1 B365.6 M
Slightly volatile
Short Term Debt57.1 M54.4 M11.6 M
Slightly volatile
Common Stock278.9 K265.6 K177.4 K
Slightly volatile
Current Deferred Revenue2.6 M2.8 M17.8 M
Pretty Stable
Non Current Liabilities Total907.5 M864.3 M240.8 M
Slightly volatile
Long Term Debt259.5 M247.1 M181.8 M
Slightly volatile
Preferred Stock Total Equity13.6814.42 M
Slightly volatile
Property Plant Equipment405.2 M385.9 M121.9 M
Slightly volatile
Other Assets229.4 K241.5 K10 M
Pretty Stable
Good Will9.2 M17.7 M13.6 M
Slightly volatile
Intangible Assets9.9 M7.9 M11.6 M
Very volatile
Other Liabilities67.6 M64.3 M36.4 M
Slightly volatile
Net Tangible Assets202.9 M300.2 M200.3 M
Slightly volatile
Long Term Debt Total1.7 M2.4 M1.8 M
Slightly volatile
Capital Surpluse1.5 B1.4 B794.6 M
Slightly volatile
Non Current Liabilities Other576.6 M549.2 M189.7 M
Slightly volatile
Long Term Investments353.5 M336.6 M139.4 M
Slightly volatile
Short and Long Term Debt48.3 M46 M22.1 M
Slightly volatile
Net Invested Capital870.5 M829.1 M304.6 M
Slightly volatile
Net Working Capital911.8 M868.4 M272.9 M
Slightly volatile
Capital Stock252.4 K265.6 K6.4 M
Pretty Stable

Arrowhead Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization22.5 M21.4 M8.4 M
Slightly volatile
Selling General Administrative106 M111.5 M56.4 M
Slightly volatile
Selling And Marketing Expenses2.1 M2.2 M1.6 M
Slightly volatile
Total Revenue1 B953.9 M218.6 M
Slightly volatile
Gross Profit3.9 M4.1 M55.5 M
Slightly volatile
Other Operating Expenses730.1 M695.3 M264.2 M
Slightly volatile
Cost Of Revenue21.6 M21.4 M30.3 M
Slightly volatile
Total Operating Expenses882.8 M840.8 M289.2 M
Slightly volatile
Research Development733.1 M698.2 M227.8 M
Slightly volatile
Non Recurring1.8 M1.8 M2.5 M
Pretty Stable
Interest Income45 M42.9 M12.3 M
Slightly volatile
Reconciled Depreciation28.9 M27.5 M10.5 M
Slightly volatile

Arrowhead Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow124 M118.1 M88.1 M
Slightly volatile
Depreciation28.9 M27.5 M9.4 M
Slightly volatile
End Period Cash Flow274 M261 M118.2 M
Slightly volatile
Stock Based Compensation79.6 M57 M38.4 M
Slightly volatile
Change To Netincome109.2 M104 M47.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.765.01544
Slightly volatile
Days Sales Outstanding2.572.7403
Slightly volatile
Average Payables6.8 M6.5 M5.5 M
Slightly volatile
Stock Based Compensation To Revenue0.08350.087910.0494
Slightly volatile
Capex To Depreciation0.810.852.5193
Slightly volatile
EV To Sales5.285.56466
Slightly volatile
Inventory Turnover0.00730.00770.1066
Slightly volatile
Days Of Inventory On Hand51.6 K49.1 K50.9 K
Slightly volatile
Payables Turnover0.510.480.5018
Slightly volatile
Sales General And Administrative To Revenue0.160.1732.2094
Slightly volatile
Average Inventory2.2 M2.1 M1.7 M
Slightly volatile
Research And Ddevelopement To Revenue0.630.6653.0047
Pretty Stable
Capex To Revenue0.02340.02465.015
Very volatile
Cash Per Share9.337.93.3164
Slightly volatile
Days Payables Outstanding5816121.5 K
Slightly volatile
Intangibles To Total Assets0.00520.00540.0812
Slightly volatile
Current Ratio4.134.384.583
Very volatile
Receivables Turnover11510997.879
Slightly volatile
Capex Per Share0.20.150.2789
Slightly volatile
Average Receivables5.2 M5 M3.4 M
Slightly volatile
Revenue Per Share7.497.132.2192
Slightly volatile
Interest Debt Per Share6.727.087.9627
Slightly volatile
Debt To Assets0.550.580.7594
Slightly volatile
Graham Number5.225.866.4016
Slightly volatile
Operating Cycle3.283.45416
Slightly volatile
Days Of Payables Outstanding5816121.5 K
Slightly volatile
Ebt Per Ebit0.220.231.2178
Slightly volatile
Quick Ratio4.114.384.5689
Very volatile
Cash Ratio1.271.332.3452
Slightly volatile
Days Of Inventory Outstanding51.6 K49.1 K50.9 K
Slightly volatile
Days Of Sales Outstanding2.572.7403
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.890.791.11
Very volatile
Fixed Asset Turnover2.742.241.4683
Slightly volatile
Debt Ratio0.550.580.7594
Slightly volatile
Price Sales Ratio4.765.01544
Slightly volatile
Asset Turnover0.690.660.2715
Slightly volatile
Gross Profit Margin0.770.460.4327
Slightly volatile

Arrowhead Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.3 B3.1 B2 B
Slightly volatile
Enterprise Value3.3 B3.1 B2 B
Slightly volatile

Arrowhead Fundamental Market Drivers

Forward Price Earnings111.1111
Cash And Short Term Investments919.4 M

Arrowhead Upcoming Events

6th of February 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of December 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
30th of September 2023
Last Financial Announcement
View

About Arrowhead Pharmaceuticals Financial Statements

Arrowhead Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Arrowhead Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Arrowhead Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Arrowhead Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue2.8 M2.6 M
Total Revenue953.9 M1 B
Cost Of Revenue21.4 M21.6 M
Stock Based Compensation To Revenue 0.09  0.08 
Sales General And Administrative To Revenue 0.17  0.16 
Research And Ddevelopement To Revenue 0.66  0.63 
Capex To Revenue 0.02  0.02 
Revenue Per Share 7.13  7.49 
Ebit Per Revenue 0.12  0.14 

Pair Trading with Arrowhead Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arrowhead Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arrowhead Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Arrowhead Stock

  0.94ACLX ArcellxPairCorr
  0.81EVGN EvogenePairCorr
  0.8RANI Rani TherapeuticsPairCorr
  0.76APLT Applied TherapeuticsPairCorr
  0.74CRBP Corbus PharmaceuticalsPairCorr
The ability to find closely correlated positions to Arrowhead Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arrowhead Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arrowhead Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arrowhead Pharmaceuticals to buy it.
The correlation of Arrowhead Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arrowhead Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arrowhead Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arrowhead Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Arrowhead Stock Analysis

When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY